Managing Acute Myeloid Leukemia: Updates from the American Society of Hematology Meeting 2011
Release Date: January-27-12
Credit Expiration Date: January-26-13
Hematologists, oncologists, and others interested in the care of patients with AML.
Acute myeloid leukemia (AML) is the most common type of leukemia among adults. AML is a rapidly progressing cancer, and without treatment, most people with AML die within 3 to 4 month of diagnosis. With treatment, about one-third of patients with AML can be cured. An estimated 12 330 new cases of AML are diagnosed in the United States each year, and approximately 8950 people die from this disease each year. Many questions remain regarding optimal evidence-based treatment approaches in AML, and new evidence is emerging to provide additional insight to help answer these questions.
Hematology/oncology clinicians have the opportunity to improve outcomes in patients with AML by expanding their awareness of new evidence-based practices and their ability to implement these practices. The goal of this continuing medical education activity is to increase knowledge and competency among hematology/oncology clinicians regarding best practices in the management of AML, ultimately improving complete remission rate and overall survival in patients with AML.
B. Douglas Smith, MD
Associate Professor of Oncology
Division of Hematologic Malignancies
Sidney Kimmel Cancer Center at Johns Hopkins
Elias Jabbour, MD
MD Anderson Cancer Center
Jessica K. Altman, MD
Assistant Professor, Department of Medicine
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Amit K. Verma, MBBS
Associate Professor of Medicine
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Dr. Smith has no relevant conflicts to disclose.
Dr. Jabbour discloses he is a consultant with Bristol-Myers Squibb, Novartis, and Pfizer.
Dr. Altman discloses she is a consultant with Celgene and Epicept.
Albert Einstein College of Medicine:
The staff of CCME of Albert Einstein College of Medicine have no conflicts of interests to report with commercial interests related directly or indirectly to this educational activity.
The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with commercial interests other than the following:
Steven Jay Feld, or a member of his household own securities in: Bioheart, Inc., Chelsea Therapeutics, Inc. and Pharmacopeia, Inc.
Amit Verma, MD has no relevant financial conflicts to disclose.
Ms. Thier has no relevant financial conflicts to disclose.
Dr. Paczolt has no relevant financial conflicts to disclose.
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and Medical Communications Media, Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
This activity was supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.
©2012, Albert Einstein College of Medicine of Yeshiva University and Medical Communications Media, Inc. All rights reserved. This publication is designed to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the contents may be reproduced in any form without prior written permission from Albert Einstein College of Medicine and the publisher. The opinions expressed in this video roundtable are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine, or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.